

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>AMGEN INC</u>  (Last) (First) (Middle) <u>ONE AMGEN CENTER DRIVE</u>  (Street) <u>THOUSAND OAKS CA 91320</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>12/11/2013</u>	3. Issuer Name and Ticker or Trading Symbol <u>TETRALOGIC PHARMACEUTICALS CORP [ TLOG ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Convertible Notes	(2)	(2)	Series C Convertible Preferred Stock	\$3,000,000	7 <sup>(2)</sup>	D	
Series B Convertible Preferred Stock	(2)	(2)	Common Stock	108,932	0 <sup>(2)</sup>	I	By Ventures <sup>(1)</sup>
Series C Convertible Preferred Stock	(2)	(2)	Common Stock	117,361	0 <sup>(2)</sup>	I	By Ventures <sup>(1)</sup>
Convertible Notes	(2)	(2)	Series C Convertible Preferred Stock	\$279,103	7 <sup>(2)</sup>	I	By Ventures <sup>(1)</sup>
Series C Convertible Preferred Stock Warrants (Right To Buy)	(2)	(2)	Series C Convertible Preferred Stock	13,355	6.4022 <sup>(2)</sup>	I	By Ventures <sup>(1)</sup>
Common Stock Warrants (Right To Buy)	(3)	(3)	Common Stock	5,564	0.85 <sup>(3)</sup>	I	By Ventures <sup>(1)</sup>

1. Name and Address of Reporting Person* <u>AMGEN INC</u>  (Last) (First) (Middle) <u>ONE AMGEN CENTER DRIVE</u>  (Street) <u>THOUSAND OAKS CA 91320</u>  (City) (State) (Zip)
---

1. Name and Address of Reporting Person* <u>Amgen Ventures LLC</u>  (Last) (First) (Middle) <u>ONE AMGEN CENTER DRIVE</u>  (Street) <u>THOUSAND OAKS CA 91320</u>  (City) (State) (Zip)
--

Explanation of Responses:

1. Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.

2. As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock will be converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock will be exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock will be issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock.

3. Represents warrants (the "Bridge Warrants") for the right to purchase common stock of the Issuer on a one-for-one basis at the exercise price reported herein. The Bridge Warrants are exercisable at the option of the holder.

/s/ David J. Scott, Senior Vice  
President, General Counsel and  
Secretary on behalf of Amgen 12/11/2013  
Ventures LLC and Amgen Inc.

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**